XAV-939(NVP-XAV939)

XAV-939(NVP-XAV939)，Cas No.:284028-89-3，是一种小分子化合物，属于选择性Wnt通路转录因子-连环蛋白介导的转录抑制剂，同时也是轴蛋白稳定剂。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。

关键词

XAV-939(NVP-XAV939)

所属分类

小分子

目录号

T1878

获取报价

猜你喜欢

产品描述
产品组分
文件资源
营销中心
注意事项
FAQ
文献追踪

XAV-939 (NVP-XAV939) 是一种 Tankyrase (TNKS) 抑制剂，抑制 TNKS1 和 TNKS2 (IC50=11/4 nM)。XAV-939 可以选择性抑制 Wnt/β-catenin 介导的转录。

生物活性

产品描述	XAV-939 (NVP-XAV939) is a Tankyrase (TNKS) inhibitor that inhibits TNKS1 and TNKS2 (IC50=11/4 nM). XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription.
靶点活性	TNKS1:11 nM (cell free), ARTD1:5500 nM, TNKS2:4 nM (cell free), ARTD2:479 nM
体外活性	方法：人结直肠癌细胞 SW480 用 XAV-939 (1 µM) 处理 16 h，使用 Western Blot 检测靶点蛋白表达水平。结果：XAV-939 降低 SW480 细胞中 β-catenin 的丰度并增加 axin 和 p-β-catenin 的丰度。[1] 方法：正常人表皮角质形成细胞 NHEK 用 XAV-939 (10-50 µM) 和 rhIL-6 (50 ng/mL) 处理 24 h，使用 APC BrdU flow kit 检测靶细胞数。结果：XAV-939 基本上抑制了 NHEK 的过度增殖。[2]
体内活性	方法：为研究 Wnt 信号的体内功能，将 XAV-939 (1 mg/mL，100 μL，10% DMSO/90% 0.9% NaCl) 腹腔注射给 IMQ 诱导的银屑病小鼠模型，每天一次，持续七天。结果：XAV-939 的给药导致小鼠 IMQ 诱导的表皮增生和真皮炎症浸润显著减少。XAV-939 给药显著减少了 IMQ 诱导的炎症皮肤病变中 F4/80+ 巨噬细胞和 CD3+T 细胞的浸润。Wnt 信号传导对 IMQ 介导的表皮增生至关重要。[2] 方法：为检测体内抗肿瘤活性，将 paclitaxel (10 mg/kg) 和 XAV-939 (10 mg/kg) 腹腔注射给携带人乳腺癌肿瘤 MDA-MB-231 的 BALB/c nude 鼠，每周两次，持续四周。结果：与对照和每种单一治疗相比，paclitaxel 和 XAV-939 的联合治疗可以有效抑制乳腺肿瘤的生长。[3]
细胞实验	XAV939, the recently identified small molecule shown to specifically inhibit PARP activity of tankyrase 1 (and tankyrase 2 at higher concentrations), was used here at much lower concentrations than 3-AB. The tankyrase specific inhibitor XAV939 was solubilized in DMSO at 55°C to a stock concentration of 10mM, which was diluted to a working concentration of 100μM; final concentrations of 0.5μM or 1μM were well within the concentration parameters suggested for cell culture experiments to inhibit tankyrase specifically. Cultures were maintained under these conditions for the duration of the designated time course. Controls were exposed to DMSO alone. Following treatment, cells were lysed and prepared for western blot analysis. Tankyrase 1 and DNA-PKcs protein levels were normalized to the β-actin loading controls and quantified [1].
动物实验	XAV-939, a selective inhibitor of tankyrase (TNKS)-1 and TNKS-2, was injected i.p., at a dose of 1 mg/ml, once a day for seven consecutive days of IMQ treatment (injection volume 100 μl). Control mice were injected with 100 μl 10% DMSO/90% 0.9% NaCl, the solvent for XAV-939 [3].
别名	XAV939, NVP-XAV939

化学信息

分子量	312.31
分子式	C₁₄H₁₁F₃N₂OS
CAS No.	284028-89-3
Smiles	FC(F)(F)C1=CC=C(C=C1)C1=NC(=O)C2=C(CCSC2)N1
密度	1.5 g/cm3

产品组分

内容	型号	规格	储存温度
XAV-939(NVP-XAV939)	T1878-01	5mg	-20°C
XAV-939(NVP-XAV939)	T1878-02	10mg	-20°C
XAV-939(NVP-XAV939)	T1878-03	25mg	-20°C
XAV-939(NVP-XAV939)	T1878-04	50mg	-20°C
XAV-939(NVP-XAV939)	T1878-05	100mg	-20°C
XAV-939(NVP-XAV939)	T1878-06	200mg	-20°C
XAV-939(NVP-XAV939)	T1878-07	500mg	-20°C
XAV-939(NVP-XAV939)	T1878-08	1mlx10mM in DMSO	-20°C
操作手册	1	1	常温

文件资源

营销中心
注意事项

保存建议厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。
FAQ
1.Huang SM, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009 Oct 1;461(7264):614-20.

2.Bai J, et al. Epigenetic downregulation of SFRP4 contributes to epidermal hyperplasia in psoriasis. J Immunol. 2015 May 1;194(9):4185-98.

3.Shetti D, et al. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling. Cells. 2019 Aug 14;8(8):892.

4.Geng W, Guo X, Zhang L, et al. Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway[J]. Biomedicine & Pharmacotherapy. 2018 Nov;107:484-494.